Cholic Acid ( DrugBank: Cholic Acid )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
20副腎白質ジストロフィー2
234ペルオキシソーム病(副腎白質ジストロフィーを除く。)3
265脂肪萎縮症1
310先天異常症候群1

20. 副腎白質ジストロフィー


臨床試験数 : 61 薬物数 : 90 - (DrugBank : 31) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004442
(ClinicalTrials.gov)
September 199718/10/1999Study of Bile Acids in Patients With Peroxisomal DisordersInfantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;AdrenoleukodystrophyDrug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiolChildren's Hospital Research Foundation University of CincinnatiChildren's Hospital Medical Center, CincinnatiTerminatedN/A5 YearsBoth25N/ANULL
2NCT00007020
(ClinicalTrials.gov)
January 19926/12/2000Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidInvestigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid MetabolismInfantile Refsum's Disease;Zellweger Syndrome;Adrenoleukodystrophy;Peroxisomal Disorders;CholestasisDrug: Cholic AcidsTravere Therapeutics, Inc.Children's Hospital Medical Center, CincinnatiCompletedN/AN/AAll85Phase 3United States

234. ペルオキシソーム病(副腎白質ジストロフィーを除く。)


臨床試験数 : 39 薬物数 : 35 - (DrugBank : 12) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004442
(ClinicalTrials.gov)
September 199718/10/1999Study of Bile Acids in Patients With Peroxisomal DisordersInfantile Refsum's Disease;Zellweger Syndrome;Bifunctional Enzyme Deficiency;AdrenoleukodystrophyDrug: chenodeoxycholic acid;Drug: cholic acid;Drug: ursodiolChildren's Hospital Research Foundation University of CincinnatiChildren's Hospital Medical Center, CincinnatiTerminatedN/A5 YearsBoth25N/ANULL
2NCT00007020
(ClinicalTrials.gov)
January 19926/12/2000Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidInvestigation in the Pathogenesis of Liver Disease in Patients With Inborn Errors of Bile Acid MetabolismInfantile Refsum's Disease;Zellweger Syndrome;Adrenoleukodystrophy;Peroxisomal Disorders;CholestasisDrug: Cholic AcidsTravere Therapeutics, Inc.Children's Hospital Medical Center, CincinnatiCompletedN/AN/AAll85Phase 3United States
3EUCTR2010-022046-25-NL
(EUCTR)
27/10/2010Cholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. - Cholic acid in ZellwegerCholic acid treatment in Peroxisomal Biogenesis Disorders (Zellweger spectrum): biochemical and clinical effects. - Cholic acid in Zellweger Peroxisomal biogenesis disorder Synonym: Zellweger spectrum disorderThis syndrome encompasses a spectrum of severity in symptomsPreviously the disorder was subdivided into three disorders based on the severity of symptoms; Infantile Refsum disease (IRD) is the mildest form, neonatal adrenoleucodystrofia (NALD) has more severe symptoms and Zellweger syndrome has the most severe clinical symptoms.
MedDRA version: 12.1;Level: LLT;Classification code 10053706;Term: Zellweger syndrome
MedDRA version: 12.1;Classification code 10038275;Term: Refsum's disease
Product Name: cholic acid
Product Code: CA
INN or Proposed INN: Cholic Acid
Other descriptive name: CHOLIC ACID
Department of Pediatric Gastroenterology, Academic Medical CentreNULLNAFemale: yes
Male: yes
Phase 2Netherlands

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00457639
(ClinicalTrials.gov)
April 20064/4/2007Cholic Acid for Hepatic Steatosis in LipodystrophyPhase II Study of Cholic Acid for Hepatic Steatosis in Lipodystrophy PatientsHepatic SteatosisDrug: Cholic AcidUniversity of Texas Southwestern Medical CenterFDA Office of Orphan Products DevelopmentCompleted6 Years70 YearsAll18Phase 2United States

310. 先天異常症候群


臨床試験数 : 11 薬物数 : 20 - (DrugBank : 10) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 7
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03720990
(ClinicalTrials.gov)
March 27, 202124/10/2018Smith-Lemli-Opitz Syndrome and Cholic AcidSmith-Lemli-Opitz Syndrome: A Pilot Study of Cholic Acid SupplementationSmith-Lemli-Opitz SyndromeDrug: Cholic AcidUniversity of NebraskaUniversity of Colorado, Denver;Children's Hospital Medical Center, Cincinnati;University of PittsburghActive, not recruiting2 Years25 YearsAll12Phase 1/Phase 2United States